EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Serum macrophage migration inhibitory factor as a predictor of radiographic progression in ankylosing spondylitis: a retrospective cohort study

Yasser A Elmotaleb Gazar, Sherif Ismail, Saad Ghanem, Mohamed Magdy Ghit, Adel Ibrahim Azzam

Clinical Rheumatology · 2026-06 · 45 (6) · 3363-3375

DOI: 10.1007/s10067-026-08063-5 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Rheumatology, online erschienen am 16.04.2026. Verfasst von Yasser A Elmotaleb Gazar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology and Rehabilitation Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Macrophage Migration-Inhibitory Factors, Spondylitis, Ankylosing, Intramolecular Oxidoreductases. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Al-Azhar University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Macrophage migration inhibitory factor (MIF) is a pleiotropic pro-inflammatory cytokine implicated in the pathogenesis of ankylosing spondylitis (AS). This study aimed to evaluate whether serum MIF levels measured at baseline are associated with radiographic progression in AS patients assessed retrospectively over time.

Methods

This retrospective cohort study with concurrent healthy controls included 50 AS patients meeting the modified New York criteria and 60 age- and sex-matched healthy controls. Serum MIF was measured by ELISA at baseline. Clinical assessment included Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Radiographic progression was assessed retrospectively using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) on radiographs obtained at baseline and at least 12 months later (median interval 24 months, range 12–36). Progressors were defined as patients with annualized mSASSS increase ≥ 1 unit/year. Two independent readers scored all radiographs while blinded to clinical data and time sequence.

Results

Serum MIF levels were significantly elevated in AS patients compared to controls (median 43.0 ng/mL vs. 11.2 ng/mL, p < 0.0001). Among AS patients, 15 (30%) were classified as progressors. After adjusting for age, sex, disease duration, baseline mSASSS, smoking, and ESR in multivariable logistic regression, elevated MIF remained independently associated with progression (OR 1.85 per 10 ng/mL increase, 95% CI 1.08–3.18, p = 0.028). MIF levels correlated with disease duration (ρ = 0.299, p = 0.035), ESR (ρ = 0.669, p < 0.0001), and mSASSS score (ρ = 0.324, p = 0.021). ROC analysis demonstrated that MIF > 51 ng/mL discriminated progressors from non-progressors with AUC 0.746 (95% CI 0.599–0.893), sensitivity 53.3%, specificity 94.3%, positive predictive value 80.0%, and negative predictive value 82.5%.

Conclusion

Baseline serum MIF is independently associated with subsequent radiographic progression in AS patients after adjustment for key confounders. While sensitivity is modest (53%), the high specificity (94%) suggests that elevated MIF (> 51 ng/mL) may help identify patients at higher risk for progressive spinal damage. Key Points • Baseline serum MIF levels are independently associated with subsequent radiographic progression in AS after adjusting for age, sex, disease duration, baseline damage, smoking, and ESR. • MIF >51 ng/mL predicts progression with high specificity (94%) but modest sensitivity (53%), suggesting utility for identifying high-risk patients rather than screening all patients. • MIF correlates moderately with ESR (ρ=0.669) but shows independent prognostic value in multivariable models, consistent with MIF's dual role in driving inflammation and bone formation. • Rigorous radiographic methodology (blinded dual readers, ICC 0.94) and detailed ELISA protocols strengthen confidence in findings, though prospective validation in larger cohorts is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macrophage Migration-Inhibitory FactorsSpondylitis, AnkylosingIntramolecular OxidoreductasesHumansFemaleDisease ProgressionRetrospective StudiesMaleAdultRadiographySeverity of Illness IndexMiddle AgedBiomarkersBlood SedimentationROC CurveC-Reactive ProteinCase-Control Studies

Stichwörter der Autor:innen

Ankylosing spondylitisBiomarkerMIFMSASSSMacrophage migration inhibitory factorModified Stoke Ankylosing Spondylitis Spine ScoreRadiographic progression

Substanzen

Macrophage Migration-Inhibitory FactorsBiomarkersIntramolecular OxidoreductasesMIF protein, humanC-Reactive Protein

Autor:innen und Institutionen

  • Rheumatology and Rehabilitation Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • Rheumatology and Rehabilitation, Internal Medicine Department, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt.
  • Rheumatology and Rehabilitation Department, Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
  • Rheumatology and Rehabilitation Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. Adelazzam191.el@azhar.edu.eg.

Förderung

  • Al-Azhar University

Zitieren

APA

Gazar, Y. A. E., Ismail, S., Ghanem, S., Ghit, M. M., & Azzam, A. I. (2026). Serum macrophage migration inhibitory factor as a predictor of radiographic progression in ankylosing spondylitis: a retrospective cohort study. Clinical Rheumatology, 45(6), 3363-3375. https://doi.org/10.1007/s10067-026-08063-5

Vancouver

Gazar YAE, Ismail S, Ghanem S, Ghit MM, Azzam AI. Serum macrophage migration inhibitory factor as a predictor of radiographic progression in ankylosing spondylitis: a retrospective cohort study. Clinical Rheumatology. 2026;45(6):3363-3375. doi:10.1007/s10067-026-08063-5

BibTeX
@article{Gazar2026,
  author = {Gazar, Yasser A Elmotaleb and Ismail, Sherif and Ghanem, Saad and Ghit, Mohamed Magdy and Azzam, Adel Ibrahim},
  title = {Serum macrophage migration inhibitory factor as a predictor of radiographic progression in ankylosing spondylitis: a retrospective cohort study},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {6},
  pages = {3363--3375},
  doi = {10.1007/s10067-026-08063-5}
}
Kostenlos starten →